KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to $898.9 million.

  • Alnylam Pharmaceuticals' Non-Current Assets rose 5.80% to $898.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $898.9 million, marking a year-over-year increase of 5.80%. This contributed to the annual value of $944.7 million for FY2024, which is 11.51% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Non-Current Assets stood at $898.9 million, which was down 2.54% from $922.3 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Non-Current Assets high stood at $945.6 million for Q1 2025, and its period low was $784.3 million during Q2 2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Non-Current Assets had a median value of $853.6 million in 2023 and averaged $878.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 35.39% in 2021, then increased by 13.13% in 2025.
  • Alnylam Pharmaceuticals' Non-Current Assets (Quarterly) stood at $834.7 million in 2021, then increased by 2.32% to $854.1 million in 2022, then dropped by 0.81% to $847.2 million in 2023, then rose by 11.51% to $944.7 million in 2024, then rose by 5.80% to $898.9 million in 2025.
  • Its Non-Current Assets was $898.9 million in Q3 2025, compared to $922.3 million in Q2 2025 and $945.6 million in Q1 2025.